Cargando…
Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
Autores principales: | Nair, Nitya, Lemmens, Ed, Enstrom, Amanda, Chen, Shih-Yu, Chang, Serena, Le, Dung, Jaffee, Elizabeth M, Maecker, Holden, Murphy, Aimee L, Brockstedt, Dirk G, Whiting, Chan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646101/ http://dx.doi.org/10.1186/2051-1426-3-S2-P102 |
Ejemplares similares
-
A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)
por: Wang-Gillam, Andrea, et al.
Publicado: (2014) -
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
por: Le, Dung T, et al.
Publicado: (2015) -
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015) -
S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014) -
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)